Han Qinghe, Li Jie, Li Zhuo, Aishajiang Reyida, Yu Duo
Department of Radiology, The Second Affiliated Hospital of Jilin University, Changchun, 130062, China.
Department of Pharmacy, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130021, China.
Mater Today Bio. 2025 Feb 20;31:101601. doi: 10.1016/j.mtbio.2025.101601. eCollection 2025 Apr.
Over the last two decades, molecular biology advances have revealed the gut microbiota's active and crucial role in colorectal cancer (CRC) pathogenesis and its dysregulation during tumorigenesis. This understanding has underscored the urgency of exploring novel therapeutic approaches to address the challenges posed by CRC. Among these approaches, nanosynergistic therapies, with their potential to modulate the gut microbiota, increase drug bioavailability and stability, and reduce side effects, have emerged as a promising avenue. Furthermore, the efficacy of nanotechnology-based approaches can be enhanced by combining them with different therapeutic methods, including chemotherapy, radiotherapy, immunotherapy, photothermal therapy, and sonodynamic therapy. Herein, recent progress in nano synergistic therapy has been reviewed, focusing on the synergy between gut microbiota and nanotechnology in CRC treatment. Additionally, the diverse applications of nanoparticles have been analyzed to provide innovative ideas and effective solutions for developing highly effective CRC treatment strategies.
在过去二十年中,分子生物学的进展揭示了肠道微生物群在结直肠癌(CRC)发病机制中所起的积极且关键的作用,以及在肿瘤发生过程中其失调的情况。这种认识凸显了探索新治疗方法以应对CRC所带来挑战的紧迫性。在这些方法中,纳米协同疗法因其具有调节肠道微生物群、提高药物生物利用度和稳定性以及减少副作用的潜力,已成为一条有前景的途径。此外,基于纳米技术的方法与不同治疗方法(包括化疗、放疗、免疫疗法、光热疗法和声动力疗法)相结合,可以提高其疗效。在此,本文综述了纳米协同疗法的最新进展,重点关注肠道微生物群与纳米技术在CRC治疗中的协同作用。此外,还分析了纳米颗粒的多种应用,以为开发高效的CRC治疗策略提供创新思路和有效解决方案。